The nation of Zimbabwe has declined a significant US health deal valued at $367m (272 million pounds) over five years due to Washington's insistence on sensitive data.
This rejection was revealed following a internal memorandum dated December was disclosed, revealing that Head of State Emmerson Mnangagwa felt the deal was "lopsided".
A government representative has since stated that the US was seeking health data for research and profit while refused to share the benefits from any future treatments.
"We must now begin the difficult and regrettable process of ending our health assistance in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont publicly.
The US Embassy noted the US had furnished more than $1.9bn in health funding to Zimbabwe over the last two decades.
A medical body in Zimbabwe has called for further negotiations to reach a agreement suitable to all parties so the country's critical HIV programme can be sustained.
Wider Context
Zimbabwe's decision follows a comparable situation in Kenya, where a high court suspended a related deal with the US after legal challenges were raised about the security of citizens' medical information.
Since returning to the presidency recently, US President Donald Trump has drastically cut overseas assistance and shut down the US Agency for International Development (USAID).
The agency had administered aid for the US government, but Trump claimed its expenditure was "wasteful" and his administration was pursuing government-to-government deals to boost transparency and responsibility.
As per statements, 16 African countries have to date signed similar health pacts, constituting more than $18.3bn in committed funds.
Specifics of the Rejected Deal
The funds for Zimbabwe would have supported "combating HIV/Aids, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"It is our view this partnership might have yielded extraordinary benefits for the people of Zimbabwe, especially the 1.2 million men, women and children presently receiving HIV treatment via American-funded initiatives," Tremont added.
However, government spokesperson Nick Mangwana maintained the arrangement was "unequal".
"Our nation was requested to provide its genetic material and health information indefinitely, without any equivalent guarantee of benefiting from any scientific breakthroughs – such as new medicines or tests – that might be developed from that provided information," he stated.
"Effectively, our nation would provide the basic resources for medical research with no certainty that the end products would be accessible to our people should a future disease outbreak arise."
Sovereignty and Global Health
He also noted that the American exit from the global health body and its pursuit of one-on-one health agreements were undermining frameworks already established via the global health agency.
Mangwana cited its Pathogen Access and Benefit Sharing system designed to manage future pandemics.
"This mechanism is intended to ensure that when a nation provides its samples, the resulting advantages – including vaccines and treatments – are shared equitably, not monopolised solely by those with the capability to develop them."
The government's concerns over the US deal "should not be misconstrued as hostility towards the US," he added.
"We welcome further discussions with our American counterparts on how subsequent collaboration could be structured in a manner that respects the sovereignty and dignity of each country."
Health Experts Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) expressed it acknowledged the official position, but recommended that negotiations must proceed since much of the nation's HIV programmes depended on external financing.
"In cases where technical issues arise, including those involving data governance or agreement terms, these can frequently be resolved through detailed discussion and negotiated safeguards," the group commented.
This impasse underscores the continuing challenges between receiving crucial international aid and protecting national sovereignty in an ever more data-driven world.